Moderna missed earnings forecasts, posting a net loss of $1.1 billion, or $2.91 per share, 23% below the expectations of analysts polled by Visible Alpha. Revenue was 4% higher than forecasts ...

US gives conditional nod to Zoetis' bird flu vaccine for poultry Healthcare & Pharmaceuticalscategory· February 14, 2025 Moderna said on Friday that the U.S. FDA paused a late-stage trial of its ...

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. It is the first time that Merck has ...

The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.

In its fourth-quarter earnings report, Moderna’s revenue was down substantially from 2023. Separately, media reports reveal anticipated cuts to the company’s digital team. Moderna continues to ...